Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06394830 · ClinicalTrials.gov registry record · Phase 2
Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)
A Phase 2 study of Interstitial Cystitis and Bladder Pain Syndrome, sponsored by Vaneltix Pharma.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 5
- Study locations
NCT06394830: Recruiting Phase 2 study of Interstitial Cystitis and Bladder Pain Syndrome, sponsored by Vaneltix Pharma.
NCT06394830 is a Phase 2 study of Interstitial Cystitis and Bladder Pain Syndrome that is actively recruiting participants, run by Vaneltix Pharma. The registered enrollment target is 50 participants, below the 360-participant average among 26 other Interstitial Cystitis trials with a reported enrollment target (86% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06394830, a Phase 2 study of Interstitial Cystitis and Bladder Pain Syndrome, is actively recruiting participants, sponsored by Vaneltix Pharma.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is an open-label study that will enroll participants with Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS). The study will assess PRN (as needed) dosing of up to 6 intravesical (via catheter) doses of VNX001 (study drug) to treat acute instances of moderate to severe bladder pain over a 14-day period. The main aim of the study is to tally the number of doses and assess pain before and after doses. The study will review the safety and tolerability of VNX001. Participants will need to attend up to seven (7) clinic visits (1 for screening and up to 6 visits for VNX001 dosing) or at least one (1) clinic visit (for a combined screening/dosing visit) and 5 telephone visits over the course of 14 days. Participants will also be asked complete a diary or telephone call each day of the study, in order to record bladder pain, urinary urgency, side effects, and medications taken.
Conditions Studied
Interventions
- DRUG VNX001
Study Locations (5)
California
- Valley Urology, Inc. - Fresno
- Prestige Medical Group - Tustin
Arizona
- Arizona Urology Specialists - Tucson
Georgia
- Georgia Urology - Cartersville
Oregon
- Oregon Urology Institute - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-12-13 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
What NCT06394830 shows while recruiting
NCT06394830 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 360-participant average among 26 other Interstitial Cystitis trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Interstitial Cystitis appearing as the primary indexed condition, and to 1 intervention - of which VNX001 is the first listed.
NCT06394830 lists 5 locations in 4 states (California, Arizona, Georgia).
Frequently Asked Questions
What is clinical trial NCT06394830 about?
NCT06394830 is a clinical study titled "Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)". This is an open-label study that will enroll participants with Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS). The study will assess PRN (as needed) dosing of up to 6 intravesical (via catheter) doses of VNX001 (study drug) to treat acute instances of moderate to severe bladder pain over a ...
What is the current status of trial NCT06394830?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2024-12-13. Estimated completion is 2026-06.
What conditions does trial NCT06394830 study?
This clinical trial studies the following conditions: Interstitial Cystitis, Bladder Pain Syndrome.
What interventions are being tested in trial NCT06394830?
The interventions under investigation include: VNX001 (DRUG).
Who is sponsoring clinical trial NCT06394830?
This trial is sponsored by Vaneltix Pharma, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06394830 being conducted?
This trial has 5 study locations across Arizona, California, Georgia, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Interstitial Cystitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06394830's enrollment target sits among peer trials
50 17th of 26 higher than 9 of 26 other Interstitial Cystitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Interstitial Cystitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Amniotic Membrane Therapy for Interstitial Cystitis/Painful Bladder Syndrome
RECRUITING · Phase 2
-
Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS
RECRUITING · Phase 2
-
Study of Biomarkers and the Relaxation Response Using Guided Imagery in Women With IC
COMPLETED · Phase 2
-
Study of U101 for Bladder Pain and/or Urgency
COMPLETED · Phase 2
-
Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment
RECRUITING · NA
-
Peppermint Oil for the Treatment of Interstitial Cystitis / Bladder Pain Syndrome
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI